Open your account
Empower yourself with cutting-edge tools, expert insights, and unrivaled features.
Summary
Strong Base Growth Drives Operational Beat! Aurobindo Pharma kickstarted FY27 with a impressive 16.3% YoY growth in revenue to Rs 9,150 Cr and a 25.2% surge in Net Profit to Rs 1,032 Cr. Fueled by stellar performance in European formulations (+25.6% YoY), growth markets (+37.7% YoY), and strategic moves like the Lannett integration and Pen-G scaling, the company is shifting into high gear for milestone monetisation. Read our detailed breakdown to explore full financial metrics and long-term outlook!
If you closely track the pharmaceutical sector, Aurobindo Pharma Ltd's Q1FY27 results bring key insights into strong global revenue momentum and key strategic developments.
Aurobindo Pharma reported robust revenue growth of 16.3% year-on-year in Q1FY27, generating Rs 9,150 Cr, supported by broad-based traction across major business segments and key international markets.
The Big Picture: Performance beat estimates across Revenue, EBITDA, and PAT. Management reaffirmed its full-year FY27 guidance of double-digit revenue growth, EBITDA margin above 21%, and absolute EBITDA in excess of Rs 8,000 Cr. Axis Securities revised its rating from BUY to HOLD due to valuation while raising the Target Price to Rs 1,600.
Did Profitability & Margins Expand?
Yes, margins showed strong expansion. Gross margins expanded by 153 basis points (bps) YoY to 60.4%, aided by a favourable business mix and ongoing operational efficiencies. Operating EBITDA grew 17.3% YoY to Rs 1,881 Cr, translating into an EBITDA margin of 20.6% (up 18 bps YoY).
What Are the Key Drivers for Aurobindo Pharma's Performance?
Aurobindo Pharma continues its transition from an investment phase to milestone monetisation across its global platforms, driven by core formulation strength, strategic acquisitions, and backward integration.
By leveraging its scale and diversified geographic presence, the company maintained strong commercial execution across developed and growth markets.
Here are the critical factors influencing the latest quarter:
- US Commercial Execution: Delivered US revenues of $399 Mn (Rs 3,770 Cr, up 8.1% YoY) with 10 new launches and 10 final approvals during the quarter.
- Lannett Integration: Completed the $247 Mn acquisition following FTC approval, boosting complex generics, controlled substances, and government market access, with gAdvair scheduled for launch in Aug'26.
- European Outperformance: Formulations surged 25.6% YoY to Rs 2,937 Cr (€267 Mn, up 11% YoY in CC) with EBITDA margins expanding above 20%.
- Pen-G & China Operations: Pen-G facility operates at 800-900 tonnes/month for captive and external supply with PLI incentives pending; China OSD plant doubled output and is turning EBITDA positive in FY27.
- Biosimilars & Innovation: CuraTeQ achieved ANVISA GMP certification, filed bDenosumab with EMA/CHMP, and is preparing 2-3 imminent USFDA filings.
A Quick Look at Q1FY27 Financials
To understand the financial health of the company this quarter, let's look at the core numbers compared to the previous year and quarter.
Here is how the metrics stack up:
- Net Sales: Increased by 16.3% YoY to Rs 9,150 Cr.
- EBITDA: Increased by 17.3% YoY to Rs 1,881 Cr.
- Reported PAT: Increased by 25.2% YoY to Rs 1,032 Cr.
The table below provides a deeper breakdown of the quarterly financials:
| Financial Metric | Q1FY27 (Rs Cr) | YoY Growth (%) | QoQ Growth (%) |
|---|---|---|---|
| Net Sales | 9,150 | 16.3 | 3.4 |
| EBITDA | 1,881 | 17.3 | 7.3 |
| EBITDA Margin (%) | 20.6 | +18 bps | +76 bps |
| Reported PAT | 1,032 | 25.2 | 12.1 |
The Takeaway:
Aurobindo Pharma successfully combined strong top-line growth with steady operating margin expansion, while keeping R&D spending disciplined as Phase 3 clinical trials conclude.
Geographical & Segment Performance Snapshot
| Geographical Segment | Revenue (Rs Cr) | YoY Growth (%) | Key Growth Drivers |
|---|---|---|---|
| USA Formulations | 3,770 | 8.1 | Generated $399 Mn; driven by volume gains, 10 new product launches, and 10 final approvals. |
| Europe Formulations | 2,937 | 25.6 | Delivered €267 Mn (up 11% YoY in CC); primary growth engine with EBITDA margins expanding above 20%. |
| Growth Markets | 1,063 | 37.7 | Reached $113 Mn, supported by robust market expansion across Canada, Indonesia, and China. |
| API Business | 1,049 | 14.6 | Betalactum grew 26.4% YoY to Rs 800 Cr; API experienced minor QoQ moderation due to seasonal antibiotic demand softness. |
The most important thing to remember: Aurobindo Pharma is strategically transitioning from capital expenditure intensity into milestone monetisation, backed by a strong net cash position of $42 Mn.
What are the Long-Term Growth Pillars?
Looking Ahead
Aurobindo Pharma's management remains confident in its growth trajectory for FY27, backed by resilient performance in the US base business, robust double-digit momentum in Europe, and expansion in Growth Markets.
With a Target Price of Rs 1,600/share based on 18x FY28E P/E, Axis Securities maintains a HOLD rating on the stock following recent strong run-ups in valuation.
Want to Learn More About Aurobindo Pharma?
Read the complete research report for detailed financial analysis, management commentary, growth outlook, and key risks shaping Aurobindo Pharma's future.
Read Full Report →
Disclaimer: This article is for information and educational purposes only. It does not constitute investment advice, trading advice, or a recommendation to buy, sell, or hold any security. Investors and traders should consult with a certified financial advisor before making any investment decisions. AI tools may have been used to assist in the creation of this article.